Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-8gtf8 Total loading time: 0 Render date: 2025-02-23T12:22:37.392Z Has data issue: false hasContentIssue false

Tolcapone

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Tolcapone (3,4-dihydroxy-4′-methyl-5-nitrobenzophenone or (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone) is a yellow, odourless, crystalline, lipophilic compound with a molecular weight of 273.24 and an empirical formula of C14H11NO5.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 485 - 493
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Artusi, CA, Sarro, L, Imbalzano, G, Fabbri, M, Lopiano, L. Safety and efficacy of tolcapone in Parkinson’s disease: systematic review. Eur J Clin Pharmacol 2021; 77(6): 817–829.CrossRefGoogle ScholarPubMed
Eggert, K, Oertel, WH, Lees, AJ. Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study. Clin Neuropharmacol 2014; 37(1): 1–5.CrossRefGoogle ScholarPubMed
Fabbri, M, Ferreira, JJ, Rascol, O. COMT inhibitors in the management of Parkinson’s disease. CNS Drugs 2022; 36(3): 261–282.CrossRefGoogle ScholarPubMed

References

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 23 May 2022 via www.medicinescomplete.com.Google Scholar
Coker, AR, Weinstein, DN, Vega, TA, Miller, CS, Kayser, AS, Mitchell, JM. The catechol-O-methyltransferase inhibitor tolcapone modulates alcohol consumption and impulsive choice in alcohol use disorder. Psychopharmacology (Berl) 2020; 237(10): 3139–3148.CrossRefGoogle Scholar
Forsberg, M, Lehtonen, M, Heikkinen, M, Savolainen, J, Järvinen, T, Männstö, PT. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther 2003; 304(2): 498–506.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 23 May 2022 via www.medicinescomplete.com.Google Scholar
Summary of product characteristics – Tasmar 100 m film-coated tablets. Mylan. Electronic Medicines Compendium: Tasmar 100 mg film-coated tablets – summary of product characteristics (SmPC) – (emc). Accessed on 23 May 2022 via www.medicines.org.uk.Google Scholar
Tolcapone. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 23 May 2022 via www.medicinescomplete.com.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Tolcapone
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.049
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Tolcapone
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.049
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Tolcapone
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.049
Available formats
×